Biogen - Extend Human Life

The company Biogen International Business Company located in Ireland will start up with the collaboration of companies and scientists from around the world a project to extend human life, thanks to blockchain technology it is now possible to participate.

STO/ICO Status

Start Date
End Date
Soft Cap
3,000,000 USD
Hard Cap
400,000,000 USD
Initial Price
1 HTER = 0.0006 ETH
Token Supply
STO/ICO Website Owner of Biogen?
Claim this listing and publish updates.


Circulating Supply40%
Restricted AreasN/A
HomepageWebsite URL
White PaperView/Download



Purpose of our Ico: The purpose of our Ico is to collect funds to be able to make the necessary clinical studies to verify the effect of telomerase on human beings. For this Biogen will reach agreements with companies and scientists from around the world.

What can Biogen do that others don’t? What we can do is to reach agreements with scientists and Biotechnology companies that other companies without the Blockchain technology could not. We do not have the need to ask for any percentage of your company to finance your project.In this way it is much easier to reach agreements by not asking any part of the company avoid certain reticences that normally occur when asking a percentage of the company, we simplify and that makes us stronger in front of others to reach agreements.

Usage of Hter Tokens: The use of the Hter tokens is very simple, it will be used to verify the e-mail address of the clients who register to buy the remedy or treatment to extend human life.
With 7450 million people in the world you will say if the token is used in case of achieving our objectives.

We understand that the use of the token is simple and has no complications, but what is wrong with doing simple things and that the blockchain technology allows us to easily verify the email accounts we think is great.

What scientific advances exist and are verified today by the scientific community? Well currently, Dr. Maria Blasco has managed to activate telomerase in mice and has managed to extend life by approximately 30 percent. Now we are beginning to do research in humans that have degenerative diseases since death is not considered a disease only you can do tests on people with these diseases.

Team View All

Pablo Cervera
Pablo Cervera
Partner and CEO
Sandra Miriam Vera
Sandra Miriam Vera
Partner & Sales manager
Massimo Garzia
Massimo Garzia
COO Director of operations
Eliana Tuni
Eliana Tuni
Director of human resources
Mirta Hinojosa
Mirta Hinojosa
Ricardo Petrucci
Ricardo Petrucci
Senior systems technician